Current Histopathologic and Molecular Characterisations of Prostate Cancer: Towards Individualised Prognosis and Therapies

Matteo Santoni; Marina Scarpelli; Roberta Mazzucchelli; Antonio Lopez-Beltran; Liang Cheng; Jonathan I Epstein; Stefano Cascinu; Alberto Briganti; James W Catto; Francesco Montorsi; Rodolfo Montironi

doi:10.1016/j.eururo.2015.05.041

Current Histopathologic and Molecular Characterisations of Prostate Cancer: Towards Individualised Prognosis and Therapies

Eur Urol. 2016 Feb;69(2):186-90. doi: 10.1016/j.eururo.2015.05.041. Epub 2015 Jun 10.

Affiliations

¹ Medical Oncology, Università Politecnica delle Marche, Azienda Ospedaliero-Universitaria Ospedali Riuniti Umberto I, GM Lancisi, G Salesi, Ancona, Italy.
² Section of Pathological Anatomy, Polytechnic University of the Marche Region, School of Medicine, United Hospitals, Ancona, Italy.
³ Department of Pathology and Surgery, Faculty of Medicine, Cordoba, Spain.
⁴ Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.
⁵ Departments of Pathology, Urology, and Oncology, The Johns Hopkins Medical Institutions, Baltimore, MD, USA.
⁶ Department of Urology, IRCCS San Raffaele Hospital, Milan, Italy.
⁷ Academic Urology Unit, University of Sheffield, Sheffield, UK.
⁸ Department of Urology, IRCCS San Raffaele Hospital, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy.
⁹ Section of Pathological Anatomy, Polytechnic University of the Marche Region, School of Medicine, United Hospitals, Ancona, Italy. Electronic address: r.montironi@univpm.it.

PMID: 26070514
DOI: 10.1016/j.eururo.2015.05.041

Abstract

Data on TMPRSS2-ERG and AR-V7 may pave the way for personalised therapy for prostate cancer (PCa) patients. Comprehensive molecular profiling can help identify multiple PCa subtypes and driving alterations. Translating these findings into clinical practice is still challenging.

MeSH terms

Carcinoma / genetics*
Carcinoma / pathology*
Carcinoma / therapy
Humans
Male
Neoplasm Grading
Neoplasm Staging
Oncogene Proteins, Fusion / genetics
Precision Medicine
Prognosis
Prostatectomy
Prostatic Neoplasms / genetics*
Prostatic Neoplasms / pathology*
Prostatic Neoplasms / therapy
Receptors, Androgen / genetics
Tumor Burden

Substances

Oncogene Proteins, Fusion
Receptors, Androgen
TMPRSS2-ERG fusion protein, human